Multicentre Phase I Randomized Double Blind Placebo Controlled Study of Subcutaneous Immunotherapy in Subjects With Allergic Rhinoconjunctivitis with or without Asthma Sensitised to Dermatophagoides Pteronyssinus.
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Allergic asthma; Allergic rhinoconjunctivitis
- Focus Adverse reactions
- 12 Dec 2011 New trial record